Search for: "Black v. Pfizer, Inc."
Results 21 - 40
of 66
Sorted by Relevance
|
Sort by Date
2 Nov 2009, 7:11 am
The Court, with two Justices not participating, also asked the Solicitor General to express views on Pfizer Inc. v. [read post]
2 Oct 2008, 12:36 pm
Danek Medical, Inc., 1999 WL 1054864, *6 (M.D. [read post]
23 Jun 2014, 12:57 pm
” Matrixx Initiatives, Inc. v. [read post]
28 Dec 2011, 1:13 pm
In the recent decision, Wendell v. [read post]
6 Jul 2010, 8:00 am
Black. [read post]
13 Mar 2024, 7:24 pm
” (see also Hoechst-Roussel Pharms., Inc. v. [read post]
1 Mar 2010, 7:11 pm
Options Exchange Inc. v. [read post]
1 Mar 2010, 7:11 pm
Options Exchange Inc. v. [read post]
22 Jan 2009, 2:06 am
Pfizer Inc., 358 F.3d 659, 661 (9th Cir. 2004) (same; physician considered warning inappropriate) (applying California law).Under these facts, if Conte were an ordinary prescription drug product liability case, plaintiff would have been out of court and out of luck, just like Motus. [read post]
9 Aug 2012, 5:00 am
Merck (Vioxx) Deposition2006-07-21 Black v. [read post]
2 Mar 2012, 6:52 am
Merck (Vioxx) Deposition2006-07-21 Black v. [read post]
18 Mar 2011, 10:04 am
Pfizer, 196 F. [read post]
2 Oct 2012, 1:08 pm
Pfizer Inc. [read post]
11 Jan 2008, 9:00 am
: (IP Spotlight)PharmaIndia: Trade mark assignment under scrutiny in a case of deceptive similarity - Doctor Morepen Limited v Yash Pharma Laboratories Limited: (Mondaq),Arrow v Merck - An early route to market for generics? [read post]
5 Apr 2013, 8:07 am
Pfizer, Inc., et al., No. 5:11-CV-69-DCB-JMR, 2013 U.S. [read post]
31 Jul 2013, 8:18 am
Pfizer, Inc., No. 2:12-CV-908-WKW [WO], 2013 U.S. [read post]
23 Aug 2021, 2:12 am
In University of Rochester v. [read post]
1 Apr 2015, 4:30 am
They dress in shorts and black socks. [read post]
29 Dec 2008, 9:00 pm
Pfizer Inc., 867 N.Y.S.2d 425 (N.Y.A.D. 2008) (state appellate holding that plaintiff's home state controls on choice of law; similar to, but much better than, Desiano); (15) Vanderwerf v. [read post]
23 Oct 2008, 10:31 am
" According to the AP (10/22, Tanner), other "drugs under examination are Genentech Inc.'s psoriasis drug Raptiva (efalizumab), which just last week the Food and Drug Administration (FDA) warned may contribute to a life-threatening brain illness and infections; and Exubera, an inhaled insulin product, linked with lung cancer risks," which "Pfizer Inc. stopped selling...last year. [read post]
